Results 291 to 300 of about 774,384 (405)

MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease. [PDF]

Rheumatology (Oxford)
Klein J, Wheeler AM, Baker JF, Yang Y, Roul P, Frideres H, Wysham KD, Kerr GS, Reimold A, Ascherman DP, Kunkel GA, Cannon GW, Monach PA, Poole JA, Thiele GM, Mikuls TR, England BR.   +16 more
europepmc   +1 more source

Impact of oxygenation strategies on outcome in acute exacerbation of interstitial lung disease. [PDF]

ERJ Open Res
Thévenin R, Gillibert A, Dognon N, Drucbert M, Lagache L, Salaün M, Cuvelier A, Girault C, Artaud-Macari É.   +8 more
europepmc   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Drug-Induced Interstitial Lung Disease in Lung Cancer Patients.

Respiration
Vanhandsaeme G, Viskens K, Van Ballaer V, De Wever W, Defraene G, Lambrecht M, Donders E, Van Mol P, Wauters E.   +8 more
europepmc   +1 more source

Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis. [PDF]

Thorax
Lee CT, Gandhi SA, Elmrayed S, Barnes H, Lorenzetti D, Salisbury ML, Stewart ID, Barber C, Peters CE, Feary J, Johannson KA.   +10 more
europepmc   +1 more source

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers

Clinical Pharmacology &Therapeutics, EarlyView.
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials.
Marella Cornelia Elizabeth van Ruissen, Menno van Diemen, Liza Botros, Ingrid Tomljanovic, Hind Achbo, Dimitra Eleftheriou, Paul Willem Schenk, Naomi Bertine Klarenbeek, Derek William Gilroy, Manon Aleida Adriana Jansen, Matthijs Moerland   +10 more
wiley   +1 more source

Incidental radiologic evidence of interstitial lung disease and time to pulmonary evaluation. [PDF]

Respir Res
Kummer R, Kubbara A, Tessier KM, Meehan T, Tholkes A, Janssen K, Kim H.   +6 more
europepmc   +1 more source

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F. Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W. Beckmann, Andreas Mackensen, Frank Dörje, Martin F. Fromm   +13 more
wiley   +1 more source

From Chaos to Clarity: Reassessing Interstitial Lung Disease Terminology. [PDF]

Am J Respir Crit Care Med
Oldham JM, Molyneaux PL.
europepmc   +1 more source